Find a Clinical Trial

Showing 101 - 110 of 238 Trials

  • Cyto-KIK TRIAL: CYTO reductive surgery in Kidney cancer plus Immunotherapy (nivolumab) and targeted Kinase inhibition (cabozantinib)

    Principal Investigator:

    Mark N. Stein, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT04322955

    Population:

    Adult

    Phase:

    II
    The purpose of this study is to determine if the use of immunotherapy nivolumab and the targeted therapy cabozantinib prior to removal of the kidney will increase the number subjects who are without any visible kidney cancer in their body at some point during the course of treatment. The study will also evaluate the changes that nivolumab and cabozantinib cause in the cells adjacent to the tumor in order to understand how the study medicines work and how cancer cells become resistant to these medicines. Are you Eligible? (Inclusion Criteria) Are you 18 years of age or older? Do you have...

  • Chemo4METPANC - A Phase 2 study with combination Chemotherapy (Gemcitabine and Nab-Paclitaxel), chemokine (C-X-C) motif receptor 4 inhibitor (BL-8040), and immune checkpoint blockade (Cemiplimab) in METastatic treatment naïve PANCreas adenocarcinoma.

    Principal Investigator:

    Gulam A. Manji, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT04543071

    Population:

    Adult

    Phase:

    II
    You are being invited to take part in this research study because you have been diagnosed with pancreas cancer that has spread to other parts of the body. The purpose of this study is to determine if combination treatment with cemiplimab, motixafortide, gemcitabine, and nab-paclitaxel is effective in decreasing tumor size and prolonging life in patients with advanced pancreas cancer. The treatment consists of both immunotherapy (cemiplimab and motixafortide) and chemotherapy (gemcitabine and nab-paclitaxel). Gemcitabine and nab-paclitaxel are approved by the Food and Drug Administration (FDA...

  • Cascade Testing In Racially/Ethnically Diverse Relatives of Patients with Breast or Ovarian Cancer (CASSIE)

    Principal Investigator:

    Katherine D Crew, MD

    Contact Number:

    212-342-5162

    Population:

    Adult

    Phase:

    II
    The study is being done to answer the following question: How can we best help women with family members who have cancer and a genetic mutation in a cancer gene make decisions about undergoing genetic testing? We are doing this study because we want to better understand if our web-based tool, RealRisks, can help women with family members who have a genetic variant make an informed decision about genetic testing. Are you Eligible? (Inclusion Criteria) 18 years or older. - Both men and women of all races and ethnic groups are eligible as probands for this trial. Only female first-degree...

  • Defining the role of ctDNA monitoring in a novel, risk stratified clinical trial for PTLD.

    Principal Investigator:

    Jennifer Effie Amengual, MD

    Contact Number:

    212-342-5162

    Population:

    Pediatrics/Adult

    Phase:

    II
    The purpose of this study is to find out if there is a benefit to giving rituximab with etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (R-EPOCH) in patients who have high-risk Bcell posttransplant lymphoproliferative disorder (PTLD), while those with low-risk disease will be spared of chemotherapy and treated with rituximab alone. Concurrently this study also wants to see how helpful a new blood test called circulating tumor DNA (ctDNA) is. This test has already helped doctors make better predictions and treatment decisions in other types of lymphoma. The goal is to...

  • EXACT: Randomized phase II trial of XL092 in combination with immunotherapy in patients who progress on Adjuvant therapy in Clear Cell RCC

    Principal Investigator:

    Karie Danielle Keera Runcie, MD

    Contact Number:

    212-342-5162

    Population:

    Adult

    Phase:

    II
    The purpose of this study is to see if study drug XL092 alone or in combination with nivolumab can treat your cancer after your cancer has progressed on adjuvant treatment. Researchers also want to look at the safety of the XL092 alone and in combination with nivolumab. We are asking you to take part in this research study because you have clear cell renal cell carcinoma (clear cell kidney cancer), and your disease has come back after adjuvant treatment (treatment given after your disease progresses from your first treatment). - XL092 is not approved by the U.S. Food and Drug Administration (...

  • Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis 2

    Principal Investigator:

    Meghna S Trivedi, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT01042379

    Population:

    Adult

    Phase:

    II
    The primary purpose of this trial is to determine whether adding new drugs to the standard initial cancer treatments for breast cancer increases the probability there there will be no residual disease (cancer cells left after many attempts to remove the cancer), compared to the initial cancer treatment alone. The intervention includes different drugs to determine which study drugs might result in better outcomes than standard treatment. Are you Eligible? (Inclusion Criteria) To be eligible for this trial patients must: have breast cancer and cannot already have had chemotherapy. be at least...

  • Long-Term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated with Gene-Modified Cells

    Principal Investigator:

    Ran Reshef, MD, MSc

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05041309

    Population:

    Adult

    Phase:

    II
    The purpose of this study is to monitor you for any delayed side effects that may possibly be related to the experimental gene-modified therapy product you received in the Kite-sponsored study for Axicabtagene ciloleucel (“axi-cel”). The main study does not involve treatment. In the re-treatment portion, you will be provided access to a second course of treatment with lymphodepleting chemotherapy and axi-cel. Axi-cel is manufactured using your own blood cells. If you meet the requirements for the retreatment part of this study, the study doctor will confirm if leftover product...

  • MRD-GUIDED SEQUENTIAL THERAPY FOR DEEP RESPONSE IN NEWLY DIAGNOSED MULTIPLE MYELOMA - MASTER-2 TRIAL

    Principal Investigator:

    Rajshekar Chakraborty, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05231629

    Population:

    Adult

    Phase:

    II
    The purpose of the study is to determine the proportion of patients with lowest minimal residual disease (MRD) response obtainable after receiving 6 cycles of study treatment. Minimal residual disease is multiple myeloma cells below the level of 1 cancer cell out of 100,000 in the bone marrow. For patients who are MRD “positive” at the end of 6 cycles of therapy, this study will answer whether more patients can become and remain MRD “negative” with autologous hematopoietic cell transplantation (AHCT) plus a new immunotherapy called teclistamab in combination with...

  • NAUTIKA1: A MULTICENTER, PHASE II, NEOADJUVANT AND ADJUVANT STUDY OF MULTIPLE THERAPIES IN BIOMARKER-SELECTED PATIENTS WITH RESECTABLE STAGES IBIII NON-SMALL CELL LUNG CANCER

    Principal Investigator:

    Catherine Shu, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT04302025

    Population:

    Adult

    Phase:

    II
    The purpose of this study is to evaluate the safety and efficacy of different experimental targeted cancer therapies (not approved by the FDA for treatment of your type of cancer) in patients who have stage IA2, IB, II, IIA or selected IIIB non-small cell lung cancer tumors that are untreated and able to be removed by surgery. The treatments that will be investigated are the study-drugs alectinib, entrectinib, and vemurafenib plus cobimetinib. Based off of individual molecular abnormalities, each participant will be assigned to either the alectinib, entrectinib, or vemurafenib plus...

  • Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas with SMO/ AKT/ NF2/CDK Pathway Mutations

    Principal Investigator:

    Mary R. Welch, MD, MS

    Contact Number:

    212-342-5162

    NCT Number:

    NCT02523014

    Population:

    Adult

    Phase:

    II
    The purpose of this study is to test good and bad effects of these two different drugs against meningioma tumors with altered genes. Today, therapy for meningioma is the same for all patients, and is not based on tumor genetic testing. This trial is trying to see if tumor genetic testing would be helpful at guiding treatment in patients with meningioma. Researchers have looked at the DNA material (genes) that can be affected in meningioma and have found several genes that are altered, or mutated. These include the genes called SMO and NF2. When the SMO or NF2 genes are altered, it can cause a...

Pages